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Background: Injectable disease-modifying drugs (DMDs) reduce the number of relapses and 
delay disability progression in patients with relapsing–remitting multiple sclerosis (RRMS). 
Regular self-injection can be stressful and impeded by MS symptoms. Auto-injection devices 
can simplify self-injection, overcome injection-related issues, and increase treatment satisfaction. 
This study investigated patient responses to an electronic auto-injection device.
Methods: Patients with RRMS (n = 63), aged 18–65 years, naïve to subcutaneous (sc) interferon 
(IFN) β-1a therapy, were recruited to a Phase IV , observational, open-label, multicenter study 
(NCT01195870). Patients self-injected sc IFN β-1a using the RebiSmart™ (Merck Serono 
S.A. – Geneva, Switzerland) electronic auto-injector for 12 weeks, including an initial titration 
period if recommended by the prescribing physician. In week 12, patients completed a question-
naire comprising of a visual analog scale (VAS) to rate how much they liked using the device, a 
four-point response question on ease of use (‘very difficult’, ‘difficult’, ‘easy’, or ‘very easy’), 
and a list of ten device functions to rank, based upon their experiences.
Results: Six patients (9.5%) discontinued the study: one switched to manual injection; two 
discontinued all treatment; three changed therapy. In total, 59 out of 63 patients (93.7%) 
  completed the VAS; 54 out of 59 (91.5%; 95% confidence interval: 81.3%–97.2%) ‘liked’ 
using the electronic auto-injector (score $6), whereas 57 out of 59 (96.6%) rated the device 
overall as ‘easy’ or ‘very easy’ to use. Device features rated as most useful were the hidden 
needle (mean [standard deviation] score: 3.3 [3.01]; n = 56), confirmation sound (3.9 [2.45]), 
and multidose cartridge (4.6 [2.32]). The least useful functions were the dose history list (8.0 
[2.57]) and dose history calendar (7.5 [2.30]).
Conclusions: These findings suggest that the electronic auto-injector may be suitable for 
patients who are new to injectable DMD therapy. Devices that simplify the injection process 
may help to ensure that patients receive the full benefits of treatment.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous 
system.1 Patients with relapsing–remitting MS (RRMS) experience episodes of acute 
worsening of neurologic function, followed by a variable degree of recovery.2 Several 
injectable disease-modifying drugs (DMDs) are available that have been shown to 
reduce relapses and that may delay progression of disability in patients with MS;3–6 
however, these drugs require frequent administration.Patient Preference and Adherence 2012:6 submit your manuscript | www.dovepress.com
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MS therapy is rapidly evolving with the recent introduction 
of oral agents in some countries, but self-injectable DMDs are 
expected to remain the first-line treatment for MS in Europe, 
because of the favorable long-term efficacy, safety, and 
tolerability data available for these agents.5,7,8 Regular self-
injections can be stressful for many patients, and symptoms 
of MS, such as cognitive impairment and impaired motor 
skills, may impede self-injection.9 Such issues, in addition to 
needle phobia, injection anxiety, perceived lack of efficacy, 
and concerns over injection-related adverse events, can 
negatively impact treatment acceptance, adherence,10–13 and, 
ultimately, efficacy.14 Adherence to long-term therapies is 
defined by the World Health Organization as “the extent to 
which a person’s behavior – taking medication, following a 
diet, and/or executing lifestyle change – corresponds with 
agreed recommendations from a healthcare provider”.15 
Adherence to treatment may be improved through patient 
education, correct injection technique, the management of 
expectations, and accurate monitoring of adherence.16
Innovative delivery devices have been designed to 
improve the injection experience and thus potentially improve 
both adherence to treatment and clinical outcomes.
Auto-injection devices are available for most DMDs 
and can simplify the injection process, overcome injection-
related issues, and improve treatment satisfaction.17,18 An 
electronic auto-injection device (Figure 1) (RebiSmart™; 
Merck Serono S.A. – Geneva, Switzerland, a branch of 
Merck Serono S.A., Coinsins, Switzerland, an affiliate 
of Merck KGaA, Darmstadt, Germany) has been   developed 
for the subcutaneous (sc) administration of interferon 
(IFN) β-1a. In an international user trial assessing the 
auto-injection device, 71.6% of patients considered the 
device ‘very suitable’ or ‘suitable’ for self-injection, and 
92.2% reported some degree of suitability. In addition, 
each device   function was rated ‘very useful’ or ‘useful’ by 
at least 80% of patients.19
The present study was performed to investigate patient 
response to an electronic auto-injection device in the UK and 
Ireland, including ease of use and the three device functions 
that patients found most useful.
Methods
study design
This was a Phase IV , observational, open-label, multicenter 
study of patient use of and response to an electronic auto-
injection device in the UK and Ireland (NCT01195870). 
Patients who were treatment-naïve to sc IFN β-1a (Merck 
Serono S.A., Rebif®; Geneva, Switzerland) were given the 
option to choose from manually injecting using a prefilled 
syringe, using the standard Rebiject™ II auto-injector 
(Merck Serono S.A. – Geneva, Switzerland), or using the 
RebiSmart™ electronic auto-injector. If patients elected to 
use the electronic auto-injector, they were invited to enter 
the study and received training in the use and maintenance 
of the auto-injection device by an MS nurse using standard 
training materials. Patients self-injected sc IFN β-1a using 
the electronic auto-injector for 12 weeks, which included an 
initial titration period if recommended by the prescribing 
physician. As per the drug label recommendations, prior to 
injection, and for an additional 24 hours after each injec-
tion, use of an antipyretic analgesic was advised to decrease 
‘flu-like’ symptoms (FLS) associated with sc IFN β-1a 
administration. This observational study did not require Inde-
pendent Ethics Committee approval within the UK, although 
approval was sought and obtained in Ireland. Patient materi-
als were approved by each site’s Research and Development 
  Committee. This study was performed in accordance with 
the International Conference on Harmonisation guidelines 
for Good Clinical Practice (European Clinical Trials Direc-
tive 2001/20/EC),20,21 all applicable local regulations, and the 
Declaration of Helsinki.22
Figure 1 The rebismart™ device. 
image reproduced with permission from Merck serono s.A. – geneva, switzerland, 
a branch of Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, 
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Patients
Patients aged 18–65 years were eligible for the study if they 
had RRMS (according to the Association of British Neurolo-
gists criteria23 in the UK and the revised 2005 McDonald 
criteria24 in Ireland); were scheduled to start sc IFN β-1a, 
administered three times weekly, for the first time; chose to 
use the electronic auto-injector; were under review by an MS 
nurse; and gave written informed consent to participate in 
the study. Patients were excluded if they did not self-inject, 
were unable to use the electronic auto-injector owing to visual 
or physical impairment, were unwilling to give informed 
consent, had a contraindication to sc IFN β-1a as defined in 
the summary of product characteristics, or had any allergy 
to antipyretic analgesics that were advised as prophylaxis 
for FLS.
Assessment
After 12 weeks, patients were assessed according to standard 
care in the patients’ usual MS clinics, and asked to complete 
a questionnaire. The questionnaire comprised of a visual 
analog scale (VAS) on which patients indicated how much 
they liked using the electronic auto-injector (10-cm scale; 
0 = ‘dislike’, 10 = ‘like’), a four-point response question on 
ease of use of the device (‘very difficult’, ‘difficult’, ‘easy’, or 
‘very easy’), and a list of ten device functions to rank based 
upon their experiences (1 = most useful function; 10 = least 
useful function; Table 1). To allow for adjustments to clini-
cal appointments or occurrence of patient holidays around 
week 12, completion of the questionnaire was permitted 
within a window of 11 to 16 weeks following training and 
initiation of treatment. In exceptional circumstances, if a 
patient could not attend the clinic within the window of 11 
to 16 weeks they were asked to complete the questionnaire 
by week 16 and return it by post. Patients who discontin-
ued using the electronic auto-injector before week 12, but 
who continued to participate in the study, completed the 
questionnaire.
study endpoints
The primary endpoint was the percentage of patients who 
liked using the device (VAS score of $6) at the end of 
the 12-week treatment period. Secondary endpoints at 
week 12 were the percentage of patients who found the 
device ‘easy’ or ‘very easy’ to use, and the top three device 
functions that patients found most useful, from a ten-point 
list of functions.
study size
The primary hypothesis was that the proportions of patients 
who liked and disliked using the electronic auto-injector 
would be unequal, and that an estimated 70% of patients 
would like using the electronic auto-injector. The null 
hypothesis was that 50% of patients would like using the 
electronic auto-injector. To reject the null hypothesis, using 
a two-sided test with 5% significance level and 80% power, 
47 patients were required. To account for an expected dropout 
rate of 25%, a total of 63 patients were necessary. Sample 
size was calculated using a one-sample χ-squared test with 
normal approximation.
statistical analysis
The ‘completers population’ was defined as all patients who 
completed the VAS. The ‘rank population’ was defined as 
all patients who ranked all ten device functions in order 
of preference. All endpoints were summarized using 
  descriptive statistics, with primary endpoint results pre-
sented as percentages with 95% confidence intervals (CIs) 
and secondary endpoint results presented as numbers with 
percentages or means with standard deviations (SDs). The 
primary hypothesis was retested in a sensitivity analysis, 
which took into account all patients who entered the study. 
Scoring for each of the ten device functions was analyzed 
using summary statistics, and ranked in ascending order, so 
that the function with the lowest mean score gave the highest 
rank. The number of weeks a patient used the electronic 
auto-injector before discontinuing was also analyzed using 
summary statistics. All statistical tests were two-sided and 
Table 1 rank and summary statistics of the recorded score for 
each of the ten device functions in the rank population
Rank Function Mean 
(standard 
deviation)
Median 
(range)
1 (most useful) hidden needle 3.3 (3.01) 2.0 (1–10)
2 Confirmation sound 3.9 (2.45) 3.0 (1–10)
3 Three doses in one 
cartridge
4.6 (2.32) 4.0 (1–10)
4 injection button  
lights up
4.7 (2.16) 5.0 (1–9)
5 stepwise injection  
guide on screen
5.6 (3.14) 6.0 (1–10)
6 Last injection indicator 5.6 (2.44) 6.0 (1–10)
7 comfort settings 5.8 (2.56) 6.0 (1–10)
8 Dose indicator 6.1 (2.19) 6.0 (1–10)
9 Dose history calendar 7.5 (2.30) 8.0 (1–10)
10 (least useful) Dose history list 8.0 (2.57) 9.0 (1–10)
Notes: n = 56. secondary endpoint: top three device functions that patients found 
most useful.Patient Preference and Adherence 2012:6 submit your manuscript | www.dovepress.com
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performed at the 5% significance level using SAS software 
(v 9.2; SAS Institute, Cary, NC).
Results
Patient disposition
A total of 63 patients were enrolled in the survey from ten 
participating sites in the UK and Ireland, between October 
2009 and September 2010. Six patients completed the ques-
tionnaire outside the protocol-specified time window of 11 
to 16 weeks. However, as this was an observational study and 
these patients returned to the clinic and completed their ques-
tionnaires between 9.9 and 18 weeks, they were included in the 
primary analysis. Six of the 63 patients (9.5%) discontinued 
the study (all of whom completed the questionnaire at discon-
tinuation). Reasons for discontinuation included a switch to 
manual sc IFN β-1a injection (n = 1 patient), discontinuation 
of all treatment (n = 2), and a change in therapy (n = 3). These 
patients had used the electronic auto-injector for a mean (SD) 
of 6.8 (2.79) weeks before discontinuation.
Patient opinion of the auto-injector
In total, 59 out of 63 (93.7%) recruited patients completed 
the VAS and were included in the completers population for 
the primary endpoint. In the completers population, 54 out 
of 59 patients (91.5%; 95% CI: 81.3%–97.2%) scored $6 
on the VAS and reported that they liked using the electronic 
auto-injector (Figure 2); mean (SD) VAS score was 8.4 (1.6). 
In the sensitivity analysis, 56 out of 63 patients (88.9%; 95% 
CI: 78.4%–95.4%) scored $6 on the VAS.
ease of device use and usefulness  
of device functions
In the population of patients who completed the survey, 
57 out of 59 patients (96.6%) rated the device as ‘easy’ 
or ‘very easy’ to use (Figure 3). The device feature rated 
as most useful by the ‘rank’ population (n = 56) was the 
hidden needle, followed by the confirmation sound, and 
having all three doses required for 1 week’s treatment 
in a single cartridge (Table 1). Other device functions 
(injection button lights up, stepwise injection guide on 
screen, last injection indicator, comfort settings, and dose 
indicator) were all ranked similarly. Patients considered 
the least useful functions to be the dose history calendar 
and dose history list.
Discussion
The electronic auto-injection device was developed to 
address some of the known factors that affect patient adher-
ence to injectable DMDs,25 as well as the concerns and 
needs of patients with MS. Needle phobia, self-injection 
psychology, forgetting to inject, injection-related pain, skin-
site reactions, and travel (eg, the need to take cumbersome 
equipment) all impact on adherence to self-medication.10,12 
This study showed that the majority of patients liked the 
auto-injection device (91.5%) and found it ‘easy’ or ‘very 
easy’ to use (96.6%), both of which may lead to increased 
treatment adherence. Furthermore, results of the sensitivity 
analysis, in which 88.9% of patients scored $6 on the VAS, 
support the primary analysis findings.
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The hidden needle was considered to be the most useful 
device function, followed by the audible cue to confirm 
  correct administration of the injection, and having three 
doses (1 week’s treatment) in a single cartridge. Concealment 
of the needle throughout the injection process was very 
important to a selection of patients who were needle phobic 
and who did not want to see the needle before or after the 
injection. A concealed needle also reduces the potential 
for patient injury through mishandling of the device, and 
it increases injection discretion. The confirmation sound 
may aid injection in out-of-sight areas, while the multidose 
cartridge increases convenience. In addition, the handheld 
device is portable, does not require refrigerated storage,26 and 
reduces waste associated with single-use prefilled syringes 
and single-use injection pens.
The least useful functions, as ranked by patients, were 
the dose history calendar and dose history list. However, in 
this 12-week study, patients may have been unaware of the 
benefits of recording dose history, and such functions may 
become more beneficial to patients for assisting long-term 
adherence. In theory, the dose history features may help to 
promote dialog between healthcare professionals (HCPs) 
and patients, which is important as treatment and device 
choice should be a joint decision. In addition, the dose his-
tory features may help HCPs to avoid escalating treatment 
in patients who are non-adherent to their present treatment 
regimen.
Although a dosing history log may not be of importance 
to patients, the data relating to dose history are likely to 
be of interest to payers, who may have access to these data 
in the UK; for instance, unused or wasted drugs cost the 
National Health Service at least £100 million (approximately 
US$165 million) every year.27 Furthermore, clinicians may 
be able to justify their choice of DMD by monitoring patient 
adherence. The incorporation of adherence data into patient 
databases may offer the potential to correlate the extent of 
drug usage to treatment outcome. The dosing log may also 
provide valuable information in clinical trials and in clinical 
practice, where assessments of efficacy may otherwise be 
influenced by the patient’s subjective reporting of adher-
ence.28 Patient training and education on use of the dosing 
log may contribute to a more accurate understanding of the 
benefits that the function offers, and increase the perceived 
usefulness of this function. The dosing log may be beneficial 
to patients with mild cognitive impairment as a memory aid, 
preventing double dosing and missed injections.
Results from this study support findings from a previous 
study, in which 95.2% of patients found the functions of 
the same device ‘easy’ or ‘very easy’ to use, and overall 
convenience was rated as the most important benefit of 
the device.19 Although a slightly different range of device 
features was ranked by patients in the previous study, 
all features, including injection confirmation sound, last 
injection display, and dose history, were rated as ‘useful’ or 
‘very useful’ by at least 80% of patients.19 Results to date 
suggest that the electronic auto-injection device may be 
suitable for patients who are not satisfied with their current 
method of self-injection or for those who are new to DMD 
therapy.
The findings of the present study must be considered in 
the context of the study limitations, including the subjective 
nature of the scales used, which are difficult to validate. 
Patients may have found it difficult to interpret differences 
between ‘very difficult’, ‘difficult’, ‘easy’, or ‘very easy’ 
when rating ease of use using a four-point response question. 
Bias may have been introduced into the study at enrollment 
as only those patients who elected to use the auto-injection 
device from a selection of DMD administration options were 
invited to participate. Cognitive function was not assessed, 
which may have been useful for determining whether the 
dosing log would be of benefit to patients with cognitive 
impairment and whether responses to the questionnaire were 
affected by patients with cognitive impairment. In addition, 
the potential benefits of the dosing log for avoiding the risk 
of double dosing may not have been clearly explained to, or 
fully understood by, patients. With only 63 patients, the study 
population was small. Further, six patients discontinued the 
study. Although study discontinuations could not reasonably 
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be attributed to the electronic auto-injection device, the 
  reasons for switching to manual injection or another therapy 
or discontinuing treatment were not recorded.
A longitudinal study with a larger sample may be more 
informative in future trials because patients with MS require 
long-term therapy. Long-term treatment has been associated 
with treatment fatigue,13 so it would be interesting to evaluate 
in patients – who are not naïve to DMDs – if switching to a 
new injection device could re-stimulate interest in injectable 
therapy and subsequently increase adherence. As patients in 
this study were naïve to treatment, they would not have been 
able to compare the additional features of  the electronic auto-
injection device with those of other injection devices. It would 
be interesting to examine treatment adherence and disease 
outcomes in patients using the electronic autoinjection 
device compared with those using other delivery methods in 
a longitudinal study. Although it will be important to assess 
device adherence in a longitudinal study, shorter studies 
are useful for identifying the factors that influence early 
device discontinuation.
Use of an auto-injection device may improve concordance, 
particularly in patients with visual or cognitive impairment, or 
impaired dexterity.18 Auto-injection devices reduce injection-
site reactions compared with manual injection,18 and 
improvements in devices to simplify the process and reduce 
discomfort have been associated with reduced injection pain 
and increased treatment satisfaction.17,19
Conclusion
The results of this study in patients with RRMS suggest that 
most patients liked the electronic auto-injection device and 
found it ‘easy’ or ‘very easy’ to use. Concealment of the 
needle throughout the injection process was found to be the 
most useful feature of the device. These findings, along with 
those of a previous study assessing the suitability of the same 
device,19 suggest that the electronic auto-injector may be 
suitable for patients who are new to injectable DMD therapy. 
Devices play an important role in the individualized treatment 
of patients receiving self-injectable DMDs and may help to 
ensure that patients receive the full benefits of treatment.
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